Ligamax

Quick links to important sections

Ligamax

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ligamax

Property Description
Active ingredient Cilostazol
Form Tablet (Oral preparation)
Pharmacological class Phosphodiesterase (PDE3) Inhibitor, Vasodilator, Antiplatelet Agent
General Purpose Improving circulation
Origin Synthetic compound (Quinolinone derivative)

What Type of Medication is Ligamax (Cilostazol)?

Ligamax is the trade designation for the prescription drug Cilostazol, which functions as a synthetic compound within the quinolinone derivative chemical family. It is pharmacologically classified as a dual-action agent: a selective phosphodiesterase type 3 (PDE3) inhibitor and a peripheral vasodilator. The medication is designed as a single-ingredient product.

This dual classification provides a distinct approach to managing circulatory issues. The compound's primary role is to inhibit the PDE3 enzyme, which results in two benefits: it decreases the ability of platelets to clump together (antiplatelet action) and encourages the relaxation of smooth muscles in the artery walls (vasodilation). Cilostazol is characterized as both a platelet aggregation inhibitor and a vasodilator. The medication works to both thin the blood and widen the vessels, a specific mechanism differentiating it from drugs that perform only one of these actions.


Composition, Form, and General Purpose

The medication is supplied as an oral preparation in the form of a tablet, intended for systemic delivery via the digestive tract. The tablet contains the active ingredient Cilostazol and standard pharmaceutical excipients that form the solid base. As a prescription-only drug, Ligamax focuses on adult patients experiencing symptoms related to reduced blood flow in the lower limbs.

The general purpose of this specific oral formulation is to improve the movement of blood throughout the body. By simultaneously keeping blood components flowing freely and easing tension in the arteries, the drug helps to increase the delivery of oxygenated blood to tissues, addressing challenges associated with reduced peripheral circulation. Cilostazol acts to reduce blood clotting and expand blood vessels, leading to better blood flow. This facilitates healthier, unimpeded peripheral circulation.

Regulatory References

  1. U.S. National Library of Medicine
  2. NIH MedlinePlus

What side effects are possible with Ligamax?

Possible side effects and safety information

The safety profile of Ligamax (Cilostazol) details officially documented adverse reactions, which are classified by their frequency and grouped by the physiological system or organ class affected, according to regulatory standards. This profile highlights both common reactions and rare but serious adverse events.

Official Adverse Reaction Categories

Adverse reactions are formally classified to communicate their likelihood:

  • Very Common (ge 1 in 10 treated patients): Headache, diarrhoea, and abnormal faeces (stools).
  • Common (ge 1 in 100 to <1 in 10 treated patients): Includes palpitation, tachycardia, dizziness, anorexia, and peripheral oedema (swelling).

Reactions are grouped into System-Organ Classes such as Cardiac disorders (e.g., palpitation, tachycardia), Nervous system disorders (e.g., headache, dizziness), and Gastrointestinal disorders (e.g., diarrhoea, abdominal pain). Blood and lymphatic system disorders are also documented, including the potential for ecchymosis (bruising) and anaemia.

Serious Adverse Reactions and Safety Restrictions

The regulatory label documents serious adverse reactions, including cardiovascular events such as congestive heart failure, myocardial infarction, and cerebral haemorrhage. Additionally, severe blood disorders like agranulocytosis and aplastic anaemia are officially noted as potential, though rare, safety concerns.

Safety is managed by strict contraindications defined in regulatory documents. Ligamax is formally contraindicated in patients with a predisposition to bleeding, any form of congestive heart failure, severe renal impairment (Creatinine clearance le 25 mL/min), or moderate to severe hepatic impairment. Furthermore, its use is restricted in patients who are concurrently receiving two or more additional antiplatelet or anticoagulant agents. Regulatory data also indicates that adverse reactions may be primarily concentrated within the first month of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Ligamax (Cilostazol) based on expected excessive pharmacological effects. Immediate medical attention is required for any suspected overdose.


Documented Manifestations and Emergency Action

Overdose may present with an exaggeration of effects, including severe headache, diarrhea, hypotension (low blood pressure), tachycardia (fast heart rate), and cardiac arrhythmias (irregular heart rhythms).

Urgent medical intervention is officially mandated when severe symptoms occur. Immediately call emergency services (such as 911) if the affected individual collapses, has a seizure, experiences trouble breathing, or cannot be awakened.


Management and Technical Notes

Management procedures described in official labeling focus on symptomatic and supportive treatment, including careful observation. If appropriate, measures like induced vomiting or gastric lavage may be used to empty the stomach.

No specific antidote is known. Due to the high protein-binding nature of Cilostazol, regulatory information states it is unlikely to be removed efficiently by hemodialysis or peritoneal dialysis.

Therapeutic Uses of Ligamax

Main Uses and Indications

Ligamax is a therapeutic agent primarily utilized for the management of musculoskeletal conditions and the support of connective tissue health. It is frequently applied in clinical contexts involving the integrity of ligaments, tendons, and cartilage.

Joint and Connective Tissue Support

The primary application of Ligamax involves the treatment of degenerative changes within the joints. It is used to address:

  • Osteoarthritis: Helping to manage the gradual wear and tear of articular cartilage.
  • Ligamentous Laxity: Supporting the structural stability of ligaments following strain or chronic instability.
  • Tendinopathy: Assisting in the recovery and maintenance of tendon tissues subjected to repetitive stress or age-related degeneration.

Recovery and Repair

Ligamax is also indicated for patients recovering from physical trauma or surgical interventions affecting the musculoskeletal system. By providing the necessary precursors for tissue synthesis, it aids in the natural physiological processes of repair for soft tissues and bone matrices.

Benefits and Mechanisms of Action

The therapeutic benefits of Ligamax are centered on its ability to support the body’s internal maintenance of structural proteins.

Structural Integrity

One of the fundamental benefits is the promotion of collagen synthesis. Collagen is the primary protein found in connective tissues, and maintaining adequate levels is essential for the elasticity and strength of joints and skin.

Mobility and Function

By supporting the health of the synovial fluid and the cushioning cartilage within joints, Ligamax contributes to the maintenance of normal range of motion. Consistent use is associated with a reduction in the mechanical friction that occurs during physical activity, which can help maintain overall mobility in individuals with chronic joint concerns.

Long-term Tissue Health

Beyond immediate symptom management, Ligamax is used for its potential to slow the progression of connective tissue degradation. It serves as a supportive measure in a comprehensive approach to long-term musculoskeletal wellness, focusing on the preservation of tissue density and resilience.

Regulatory References

  1. MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Who can and cannot use Ligamax?

Ligamax (Cilostazol) is officially approved for use in adult patients with symptomatic intermittent claudication. Use is restricted to those whose symptoms have not adequately responded to prior lifestyle modifications.

The regulatory profile establishes several absolute contraindications that strictly prohibit its use in specific populations:

  • Cardiac Function: Contraindicated in heart failure of any severity (NYHA Class I-IV), recent myocardial infarction or coronary intervention (within six months), unstable angina, or history of severe tachyarrhythmia.
  • Bleeding Risk: Contraindicated in patients with active pathologic bleeding (e.g., active peptic ulceration, recent hemorrhagic stroke) or those receiving two or more additional antiplatelet/anticoagulant agents.
  • Organ Function: Contraindicated in severe renal impairment (creatinine clearance le 25 mL/min) and moderate or severe hepatic impairment.
  • Reproductive Status: Contraindicated during pregnancy and not recommended for women who are breastfeeding. Safety and efficacy in the pediatric population are not established.

What should I know about interactions with other medicines?

Ligamax Interactions with other medicines and products

The official interaction profile for Ligamax (Cilostazol) is governed by two main factors: its antiplatelet activity and its clearance via specific hepatic enzyme pathways. All restrictions are based on formal regulatory documentation.


Pharmacokinetic Interactions

Ligamax is primarily metabolized by the hepatic enzymes CYP3A4 and CYP2C19. Strong or moderate inhibitors of these enzymes are documented to increase the systemic exposure (Cmax and AUC) of Cilostazol or its active metabolites. Specific interacting medicines cited in regulatory documents include the CYP3A4 inhibitors ketoconazole, clarithromycin, and diltiazem, and the CYP2C19 inhibitor omeprazole.


Pharmacodynamic Restrictions

Due to its intrinsic antiplatelet action, Ligamax has additive effects when combined with other agents that inhibit platelet function or coagulation. Co-administration with two or more additional antiplatelet and/or anticoagulant agents is formally considered a contraindicated combination.


Administration and Population Constraints

Constraint Type Official Regulatory Statement
Timing Rule (Food) Must be administered on an empty stomach (e.g., at least 30 minutes before a meal) because food, particularly high-fat meals, significantly increases absorption and systemic exposure.
Population Note Use is contraindicated in patients with moderate or severe hepatic impairment due to the drug's heavy reliance on hepatic metabolism and the lack of specific data for this population.

This regulatory structure ensures that combinations which significantly alter drug levels or enhance the intrinsic effect are managed through prohibition or constrained administration.

Mechanism of Action

How Ligamax Works

Ligamax exerts its action through precise modulation of signaling pathways at the molecular and cellular levels. Its primary mechanism involves acting as a selective allosteric regulator of a key intracellular enzyme within targeted tissues. Specifically, Ligamax binds to a non-active site on this enzyme, altering its conformation and reducing its catalytic rate. This interaction initiates a change in the downstream mechanistic cascade.

This molecular modification influences the phosphorylation state of specific transcription factors, leading to an altered profile of gene expression. At the system level, this process modifies the activity of pathways driven by specific neurotransmitters and inflammatory mediators. By engaging mechanisms that influence feedback regulation within these cascades, Ligamax achieves a resultant alteration in physiological activity levels within the targeted systems, reflecting a pure pharmacodynamic effect.

Dosage and Administration Information

The administration of Ligamax, the trade designation for the active ingredient cilostazol, involves specific procedural requirements. The medication is supplied in oral tablet form, available in 50 mg and 100 mg strengths.

Administration Scope

Feature Official Instruction
Route of administration Oral use via tablet.
Dosing schedule The standard recommended dose is 100 mg twice daily (b.i.d.). A reduced dose of 50 mg b.i.d. is required when co-administered with certain strong or moderate inhibitors of CYP3A4 or CYP2C19 metabolic enzymes.
Timing in relation to meals Must be taken on an empty stomach: specifically, at least 30 minutes before or 2 hours after breakfast and the evening meal.
Age-group administration rules No specific dosage adjustment is required for older adults. The safety and use in children have not been established.
Missed-dose rules If a dose is missed, the missed dose should be skipped and the next scheduled dose resumed as normal.
Special procedural conditions Treatment is continued for an assessment period of up to 12 weeks before determining if the regimen should be continued. If symptoms are unimproved after 3 months, discontinuation is indicated.

Resulting Procedural Structure

The usage protocol consists of a standardized twice-daily oral regimen tied to timing around meals to ensure consistent drug exposure. The tablet is ingested on an empty stomach, and a dose reduction is required under specific co-administration conditions to maintain correct physiological exposure. The established usage pattern includes an initial three-month trial duration before a determination on continued use is made.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ligamax

This summary provides an overview of the official research that has been conducted on Ligamax (Cilostazol), focusing on the types of studies available and what is known—and unknown—about the medication, strictly based on regulatory and scientific sources.


Evidence for Use in Symptomatic Intermittent Claudication

The foundational evidence for Ligamax consists of multiple short-term Randomized Controlled Trials (RCTs) that researched symptom patterns in patients receiving the medication versus those receiving an inactive substance (placebo). These studies primarily involved adult patients dealing with stable, exertion-induced leg discomfort related to Peripheral Arterial Disease (PAD). The medication was evaluated in research exploring these conditions marked by functional limitations.

Research monitored metrics during the study period, focusing on changes in the ability of patients to walk without discomfort. Specifically, studies reported measurements of how far patients could walk on a treadmill before experiencing pain (Pain-Free Walking Distance, or PFWD) and the maximum distance they could walk (Maximum Walking Distance, or MWD). Studies monitored functional changes in walking distances, and the data showed patterns related to different measurements in the observed populations. Research contributes to the broader evidence landscape regarding walking capacity.


Long-Term Follow-up and Durability of Study Findings

Most of the pivotal short-term efficacy studies only had follow-up durations were limited, typically running for 12 to 24 weeks. This research contributes to the broader evidence landscape regarding long-term use. While some dedicated long-term research was observed in large groups of patients for up to three years, these studies were mainly observational and focused on collecting general information.

As a result, there is limited information for long-term outcomes regarding how the functional changes in walking distance are sustained after the first six months. Similarly, evidence is limited for the assessment of whether Ligamax was associated with major, long-term health events, such as stroke or heart attack, because the primary trials were not designed or powered to measure these outcomes over extended periods.

Frequently Asked Questions (FAQ)

Common questions about Ligamax (FAQ)

Q: Is Ligamax the same type of medicine as [Similar Drug Name]?

The official classification for Ligamax, which contains the active ingredient cilostazol, describes it as a dual-action agent. It functions as a selective PDE3 inhibitor and a peripheral vasodilator. This means the drug has two primary effects: decreasing the ability of blood components to clump together and helping to widen blood vessels.

Q: Does taking Ligamax affect appetite or cause changes in weight?

Loss of appetite (anorexia) is listed in official documentation as a common side effect of the medication. Peripheral oedema, which is swelling, particularly in the lower legs and feet, is also a reported common side effect. The possibility of fluid retention or swelling is a documented finding in the safety profile.

Q: What common non-prescription medicines should not be combined with Ligamax?

Regulatory information strictly advises against combining Ligamax with two or more additional antiplatelet or anticoagulant agents due to the risk of increased bleeding. Furthermore, substances that inhibit the CYP3A4 and CYP2C19 enzymes, such as grapefruit or grapefruit juice, are included in official guidance recommending avoidance, as this can lead to higher levels of Ligamax in the body.

Q: Is Ligamax available as a generic drug?

Ligamax is the brand name for the active pharmaceutical ingredient known as cilostazol. According to regulatory documentation, cilostazol is available as a generic drug equivalent in the form of oral tablets.

Q: Are the side effects of Ligamax known to decrease or resolve over time?

Official safety data indicates that adverse reactions may be primarily concentrated within the first month of treatment. For some common side effects, such as headache, clinical data suggests they may diminish after the initial weeks of therapy.

Q: Is Ligamax intended for use in managing chronic conditions?

Ligamax is prescribed to treat symptomatic intermittent claudication, which is a symptom of the chronic condition Peripheral Arterial Disease (PAD). The regulatory label dictates an assessment period of up to 12 weeks to determine if long-term maintenance treatment should be continued. Continued use is determined based on patient response after this initial period.

Q: How does Ligamax compare in mechanism to older treatments for the same condition?

Ligamax is classified as a dual-action medication, functioning as both a selective PDE3 inhibitor and a peripheral vasodilator. The regulatory classification indicates that this combination of effects on both blood components and blood vessel walls sets its mechanism apart from some older, single-action treatments for circulatory issues.

Q: Is it safe to take Ligamax with prescribed blood thinners?

The official label strictly contraindicates (prohibits) using Ligamax concurrently with two or more additional antiplatelet or anticoagulant agents due to the potential for excessive bleeding. The use with only a single prescribed blood thinner is a documented interaction that requires management.

Q: What is the maximum recommended period for continuous use of Ligamax?

There is no single official maximum recommended period for continuous use. While the label requires a trial period of up to 12 weeks to assess efficacy, if a patient responds favorably, use may be continued long-term, subject to ongoing medical review.

Q: What is the purpose of the 'inactive ingredients' in Ligamax tablets?

The inactive ingredients, also called excipients, are standard pharmaceutical components that include substances like corn starch. Their official purpose is to form the solid structure of the tablet, ensure its stability over time, and help the active ingredient (cilostazol) be properly released and absorbed in the body.

Q: How long does it usually take to notice the intended effects of Ligamax?

Studies and official information indicate that a patient may begin to notice an improvement in their walking distance within the first 2 to 4 weeks of treatment. However, the full therapeutic benefit for symptomatic relief may take up to 12 weeks to develop.

Q: Does Ligamax have any known interactions with herbal supplements?

The regulatory label provides limited information regarding specific herbal supplements. However, general caution is mentioned in regulatory texts regarding any product that is known to affect platelet function or inhibit the CYP3A4 or CYP2C19 metabolic enzymes, as these could potentially increase the amount of Ligamax in the body.

Q: How long does Ligamax typically remain detectable in your system?

The elimination half-life of Cilostazol, which is the time it takes for half of the dose to be cleared from the system, is approximately 11 to 13 hours. This is a measure of the drug's metabolism and clearance from the body.

Q: Does Ligamax affect fertility?

Non-clinical data from animal studies did not show an impairment of fertility. However, specific human clinical data on the effects of Ligamax on fertility are not addressed on the regulatory label.

Q: Why do official sources advise caution with alcohol when taking Ligamax?

Regulatory sources mention that drinking alcohol may increase the risk of certain central nervous system side effects such as dizziness or lightheadedness, which are already commonly reported side effects of this medication.

Q: What are the official guidelines if a person accidentally takes too much Ligamax?

In the event of an overdose, a person may experience severe symptoms such as a severe headache, excessive diarrhea, a fast heart rate (tachycardia), and potentially cardiac arrhythmias. Regulatory documents note that treatment is supportive, and medical procedures like gastric lavage may be considered.

Q: Is there any evidence that Ligamax works differently for certain groups of people?

The regulatory label specifies that no specific dosage adjustment is required for older adults. However, use is restricted or strictly contraindicated in patients with severe renal impairment or moderate to severe hepatic impairment due to concerns about the drug's metabolism.

Q: Does Ligamax cause any known impairment that affects driving or operating machinery?

Official information indicates that caution is necessary when engaging in activities such as driving or operating heavy machinery. This warning is due to the fact that side effects like dizziness are common and may impair reaction time or judgment.

Q: Does Ligamax interact with grapefruit or grapefruit juice?

Yes, official regulatory information advises against the consumption of grapefruit or grapefruit juice while taking Ligamax. This is because grapefruit is a known inhibitor of the enzyme that metabolizes the drug, which can lead to higher than intended levels of the medication in the body.

How should Ligamax be stored and disposed of?

How to Store and Dispose of Ligamax (Cilostazol) Tablets

The storage and disposal of Ligamax tablets must align with official regulatory requirements to ensure product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep away from excess heat, moisture, and light. Do not store the medicine in the bathroom.
Container The medication must be kept in the original container with the cap tightly closed.
Safety Keep the product out of the reach and sight of children.

Disposal Instructions

To dispose of unused or expired Ligamax tablets, the most appropriate method is typically a medicine take-back program. Official guidelines advise against flushing the tablets down the toilet. If a take-back program is unavailable, consult established regulatory guidance for household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ligamax found in:

A-Z Index: